[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 39 of about 39
1. Glória Silva F, Paiva M, Tavares A, Lacerda A, Pereira G, Marques A, Barata D, Cabral J: [Paediatric Burkitt lymphoma presenting as acute pancreatitis]. Acta Med Port; 2008 Sep-Oct;21(5):515-20
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Paediatric Burkitt lymphoma presenting as acute pancreatitis].
  • [Transliterated title] Pancreatite aguda como manifestação de linfoma de Burkitt em idade pediátrica.
  • Serial sonographic and computed tomography evaluations were suggestive of an infiltrative process of the gastric wall.
  • Endoscopy showed an infiltrative tumor of the gastric mucosa and duodenum with a giant ulcer.
  • Biopsies were compatible with Burkitt Lymphoma confirmed by ascitic fluid cytology and cytometry.
  • After staging (stage III), the patient was treated according to FAB LMB 96 chemotherapy protocol, achieving complete remission.
  • Acute pancreatitis and cholestasis are rare presentations of lymphoma in the paediatric age group.
  • [MeSH-major] Burkitt Lymphoma / complications. Pancreatitis / etiology

  • Genetic Alliance. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19187696.001).
  • [ISSN] 1646-0758
  • [Journal-full-title] Acta médica portuguesa
  • [ISO-abbreviation] Acta Med Port
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


2. Madani A, Benhmiddoune L, Zafad S, Harif M, Quessar A, Benchekroun S: [Treatment of childhood Burkitt lymphoma according to LMB89 protocol in Casablanca]. Bull Cancer; 2005 Feb;92(2):193-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of childhood Burkitt lymphoma according to LMB89 protocol in Casablanca].
  • [Transliterated title] Traitement du lymphome de Burkitt de l'enfant par le protocole LMB89 à Casablanca.
  • During the two last decades, the prognosis of children with Burkitt lymphoma has improved dramatically.
  • Treating patients with Bukitt lymphoma in countries with limited resources is a challenge.
  • We report our results in a serie of 95 children with Burkitt lymphoma treated between September 1990 and December 2000 according to SFOP LMB89 protocol.
  • Seventy three percent of patients had abdominal tumor and 10% had maxillary tumor.
  • According to Murphy classification, one patient had stage I, 17 patients stage II, 60 patients stage III and 17 patients stage IV.
  • When considering the LMB prognosis groups, 1 patient was in group A, 83 were in group B and 11 were in group C. 73 patients were evaluables for treatment results.
  • 18 patients died from early treatment toxicity.
  • It was at 100%, 84%, 52% and 38% for stage I, II, III and IV respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15749649.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate; LMB89 protocol
  •  go-up   go-down


3. Pillon M, Di Tullio MT, Garaventa A, Cesaro S, Putti MC, Favre C, Lippi A, Surico G, Di Cataldo A, D'Amore E, Zanesco L, Rosolen A: Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92). Cancer; 2004 Jul 15;101(2):385-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92).
  • BACKGROUND: Childhood B-cell lymphomas (B-NHLs) represent a group of aggressive malignancies that are amenable to high-intensity chemotherapy regimens.
  • In 1992, the Italian Association of Pediatric Hematology and Oncology (AIEOP) initiated a prospective clinical trial involving the diagnosis and treatment of childhood B-NHL based on a well established strategy developed by the Berlin-Frankfurt-Munster Group.
  • Disease staging was performed according to the St. Jude staging system, and treatment was assigned on the basis of risk group (R1, R2, or R3), which took into account disease stage and resectability and serum lactate dehydrogenase (LDH) levels.
  • RESULTS: Of the 144 evaluable patients, 11 had Stage I disease, 35 had Stage II disease, 76 had Stage III disease, and 22 had Stage IV disease.
  • Multivariate analysis indicated that age > or = 10 years, disease histology other than Burkitt or Burkitt-like lymphoma, and LDH levels > or = 1000 international units per liter had negative prognostic value.
  • Analysis of the toxicity (according to the World Health Organization grading system) associated with 710 of the 748 chemotherapy cycles administered revealed 855 cases of Grade 3 or 4 toxicity, with 73% being cases of hematologic toxicity.
  • Toxic episodes were most common after the first chemotherapy cycle and were equally common in the R2 and R3 risk groups.
  • CONCLUSIONS: Long-term follow-up of the current study (AIEOP LNH92) confirms the observation of a favorable outcome for patients with B-NHL treated with short, intensive chemotherapy regimens and raises the possibility that non-Burkitt or non-Burkitt-like histology and age > or = 10 years may have negative prognostic value for patients with childhood B-NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. Italy. Male. Neoplasm Recurrence, Local. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15241838.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Jost LM, Honegger HP, Stahel RA: [High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich]. Schweiz Med Wochenschr; 2000 Jan 22;130(3):60-9
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich].
  • [Transliterated title] Hochdosis-Chemotherapie mit autologer Stammzelltransplantation: 11 Jahre Zürcher Erfahrung.
  • High-dose chemotherapy with autologous bone marrow or peripheral blood stem cell transplantation has gained widespread acceptance for the treatment of certain malignancies.
  • Since the introduction of this therapy in 1988 we have treated 272 patients.
  • Indications for high-dose chemotherapy were high-risk large cell lymphoma and lymphoblastic or Burkitt lymphoma in first remission (73 patients), non-Hodgkin's lymphoma in chemosensitive relapse (65 patients), Hodgkin's lymphoma in relapse (52 patients), germ cell tumours with inadequate response to chemotherapy (34 patients), multiple myeloma (29 patients), and other malignancies (19 patients).
  • Treatment mortality was 1.8%.
  • High-dose chemotherapy with autologous stem cell transplantation has become a safe procedure and is considered the treatment of choice for relapsed large cell lymphoma, relapsed Hodgkin's disease, stage II or III multiple myeloma, and germ cell tumours with inadequate response to cisplatin-based chemotherapy.
  • In other situations, including aggressive lymphoma with risk factors, acute leucaemia or breast cancer, the superiority of high-dose over conventional chemotherapy remains to be proven.
  • Patients with such diseases should not receive high-dose chemotherapy outside a controlled clinical study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Hematopoietic Stem Cell Transplantation. Lymphoma / therapy. Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Switzerland. Time Factors. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10683881.001).
  • [ISSN] 0036-7672
  • [Journal-full-title] Schweizerische medizinische Wochenschrift
  • [ISO-abbreviation] Schweiz Med Wochenschr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] SWITZERLAND
  •  go-up   go-down


5. Hesseling PB: High-dose intense chemotherapy in South African children with B-cell lymphoma: morbidity, supportive measures, and outcome. Med Pediatr Oncol; 2000 Feb;34(2):143-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose intense chemotherapy in South African children with B-cell lymphoma: morbidity, supportive measures, and outcome.
  • The tolerance and efficacy of short, high-dose intense chemotherapy for B-cell lymphomas in such a population were unknown.
  • PROCEDURE: Nineteen consecutive children diagnosed with B-cell lymphoma after 1993 at Tygerberg Hospital (TBH) in the Republic of South Africa (RSA) were treated according to the LMB-89 protocol.
  • RESULTS: Among the 19 children treated according to the LMB-89 protocol, there were 3 children in group A (completely resected St. Jude stage I and abdominal stage II), 14 in group B (nonresected stage I, nonabdominal stage II, all stage III, stage IV with bone marrow involvement but <70% Burkitt cells and without CNS involvement) and 2 in group C (patients with >70% Burkitt cells in bone marrow and/or CNS involvement).
  • CONCLUSIONS: A major step forward was achieved for South African children with B-cell lymphoma.
  • Our findings suggest that treatment centres that cannot measure methotrexate (MTX) serum levels should not exceed 3.0 g/m(2) of MTX.
  • If supportive care facilities are limited, consideration should be given to reducing the doses of cyclophosphamide and of doxorubicin in the treatment schedules.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Child. Child, Preschool. Female. Humans. Infant. Male. South Africa. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10657879.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Hesseling PB, Molyneux E, Kamiza S, Broadhead R: Rescue chemotherapy for patients with resistant or relapsed endemic Burkitt's lymphoma. Trans R Soc Trop Med Hyg; 2008 Jun;102(6):602-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rescue chemotherapy for patients with resistant or relapsed endemic Burkitt's lymphoma.
  • Patients with endemic Burkitt's lymphoma who failed primary treatment with the Malawi 2002 or 2003 Burkitt's lymphoma treatment protocols, consisting of high frequency cyclophosphamide 40 mg/kg and intrathecal methotrexate, were offered rescue chemotherapy.
  • Treatment consisted of cyclophosphamide 60 mg/kg and vincristine 1.5 mg/m(2) i.v. on Days 1, 8 and 15, plus intrathecal methotrexate on the same days in those patients treated for a relapse.
  • The majority of patients (81%) had St Jude stage III or IV disease.
  • Day 8 treatment was delayed in eight children and Day 15 treatment in five patients, both for a median of 7 days, mainly due to neutropenia.
  • This simple 15-day chemotherapy schedule salvaged 36% of patients and significantly increased the overall cure rate of our Burkitt's lymphoma patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417177.001).
  • [ISSN] 0035-9203
  • [Journal-full-title] Transactions of the Royal Society of Tropical Medicine and Hygiene
  • [ISO-abbreviation] Trans. R. Soc. Trop. Med. Hyg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


7. Liu MT, Hsieh CY, Wang AY, Pi CP, Chang TH, Huang CC, Huang CY: Primary breast lymphoma: a pooled analysis of prognostic factors and survival in 93 cases. Ann Saudi Med; 2005 Jul-Aug;25(4):288-93
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary breast lymphoma: a pooled analysis of prognostic factors and survival in 93 cases.
  • BACKGROUND: Primary breast lymphoma is a rare disease.
  • We conducted a pooled analysis to evaluate the treatment outcome and prognostic factors in patients with primary breast lymphoma.
  • Treatments included single therapy or combined surgery, chemotherapy and radiotherapy.
  • We analyzed the correlation between treatment protocols, tumor relapse and survival.
  • Histopathology and cancer stage were analyzed to evaluate their significance in treatment outcome.
  • The histopathology of 63 patients (68%) was diffuse large cell lymphoma.
  • According to Ann Arbor classification, 57% were stage I, 23% were stage II, 4% were stage III, and 16% were stage IV.
  • Thirteen percent received surgery alone, 27% received chemotherapy alone, 7% received radiotherapy alone, 10% received surgery and chemotherapy, 10% received surgery and radiotherapy, 22% received chemotherapy and radiotherapy, and 11% received surgery combined with chemotherapy and radiotherapy.
  • The mean time to first tumor relapse after treatment was 20 months.
  • Radiotherapy was a significant prognostic factor predicting tumor relapse (P=0.044).
  • Tumor stage was a significant prognostic factor affecting overall survival, disease-free survival and disease-specific survival (P=0.0231, 0.0015, 0.0124, respectively).
  • Patients who received chemotherapy and radiotherapy had better survival outcome and a lower relapse rate.
  • We suggestthat chemotherapy and radiotherapy be the initial treatment for patients with primary breast lymphoma.
  • [MeSH-major] Breast Neoplasms / diagnosis. Lymphoma / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / therapy. Disease-Free Survival. Female. Humans. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / epidemiology. Lymphoma, B-Cell, Marginal Zone / therapy. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / epidemiology. Lymphoma, Follicular / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / therapy. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16212120.001).
  • [ISSN] 0256-4947
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


8. Spreafico F, Massimino M, Luksch R, Casanova M, Cefalo GS, Collini P, Ferrari A, Polastri D, Terenziani M, Gasparini M, Fossati-Bellani F: Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children. J Clin Oncol; 2002 Jun 15;20(12):2783-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children.
  • PURPOSE: To improve the 63% event-free survival (EFS) achieved before 1986 in Murphy's stage III to IV Burkitt's lymphoma (BL), both chemotherapy and supportive care were intensified.
  • After 5-week cytoreductive chemotherapy consisting of vincristine, cyclophosphamide, doxorubicin, high-dose (HD) methotrexate (MTX), and intrathecal MTX or cytarabine, HD cytarabine and cisplatin were provided as a 4-day continuous infusion.
  • Six patients, two of whom were receiving regimen II, died as a result of initial treatment failure or relapse, and five patients, none receiving regimen II, died as a result of treatment-related complications.
  • CONCLUSION: This 45-day intensive chemotherapy program is the shortest schedule for disseminated BL and overcomes previously recognized risk factors such as BM and CNS infiltration.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Central Nervous System Neoplasms / secondary. Child. Child, Preschool. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Infusions, Intravenous. Injections, Spinal. Male. Methotrexate / administration & dosage. Palliative Care. Prognosis. Risk Factors. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12065554.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


9. Di Nicola M, Carlo-Stella C, Mariotti J, Devizzi L, Massimino M, Cabras A, Magni M, Matteucci P, Guidetti A, Gandola L, Gianni AM: High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults. Br J Haematol; 2004 Sep;126(6):815-20
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults.
  • A very short, intensive paediatric chemotherapy programme was tested in a consecutive monoinstitutional group of 22 adult Burkitt's lymphoma (BL) patients.
  • Responding patients achieving less than complete response (CR) after completion of the initial induction phase, were promptly shifted to a high-dose, stem cell supported sequential chemotherapy schema (R-HDS).
  • PATIENT CHARACTERISTICS: median age, 35.5 (range 18-76) years; Ann Arbor stage I-II/III-IV, 11/11; bulky disease, 15 patients; LDH > or = 460 U/l, 11 patients.
  • The median duration of the chemotherapy programme was 62 d (range, 43-94 d).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Leucovorin / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Retrospective Studies. Salvage Therapy. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15352985.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


10. Martens C, Hodgson DC, Wells WA, Sun A, Bezjak A, Pintilie M, Crump M, Gospodarowicz MK, Tsang R: Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2006 Mar 15;64(4):1183-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin's lymphoma.
  • PURPOSE: Patients with chemotherapy-resistant lymphoma have rapidly progressive disease and a poor prognosis.
  • The radiation dose was 39.9-40.5 Gy in 30 fractions.
  • The median treatment time was 22 days with twice-daily involved-field RT.
  • The initial diagnosis was Stage I-II in 56% and Stage III-IV in 44%.
  • The histologic features at diagnosis were follicular in 11 (Grade 1 in 4, Grade 2 in 3, and Grade 3 in 4), diffuse large B-cell in 14, peripheral T-cell lymphoma in 2, Burkitt-like in 1, mantle cell in 2, natural killer cell in 2, plasmacytoma/lymphoma in 1, and T-cell lymphoblastic in 1.
  • The initial treatment was chemotherapy in 32 patients (94%); 71% were refractory to initial chemotherapy and 29% developed a relapse after an initial response.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Dose Fractionation. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Remission Induction. Survivors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16376490.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Hoffmeier A, Semik M, Schmid Ch, Mesters RM, Castrucci M, Baba HA, Fallenberg EM, Scheld HH: [Primary Burkitt lymphoma of the heart--diagnosis and therapy]. Z Kardiol; 2002 Apr;91(4):347-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary Burkitt lymphoma of the heart--diagnosis and therapy].
  • [Transliterated title] Primäres Burkitt-Lymphom des Herzens--Diagnose und Therapie.
  • An 85-year-old patient suffered from progressive deterioration (NYHA III) for several months.
  • Echocardiography as well as a CT scan of the heart revealed a heart tumor to be the cause.
  • Tumor staging was negative.
  • After transvenous biopsy, the diagnosis of a Burkitt lymphoma could be established.
  • Due to the advanced age of the patient, the intended surgical therapy was turned down and the patient was treated with 6 courses of a potentially therapeutic chemotherapy (CHOP scheme), which was well tolerated by the patient.
  • The following CT scan showed a complete remission of the tumor.
  • Six months after chemotherapy the patient is in NYHA stage I.
  • [MeSH-major] Burkitt Lymphoma / radiography. Heart Atria / radiography. Heart Neoplasms / radiography
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Humans. Male. Prednisone / administration & dosage. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12063708.001).
  • [ISSN] 0300-5860
  • [Journal-full-title] Zeitschrift für Kardiologie
  • [ISO-abbreviation] Z Kardiol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


12. Hesseling P, Broadhead R, Mansvelt E, Louw M, Wessels G, Borgstein E, Schneider J, Molyneux E: The 2000 Burkitt lymphoma trial in Malawi. Pediatr Blood Cancer; 2005 Mar;44(3):245-50
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The 2000 Burkitt lymphoma trial in Malawi.
  • BACKGROUND: We previously reported 57% 12-month event free survival (EFS) in Malawian children with stage I to III Burkitt lymphoma (BL) with an intermediate dose chemotherapy protocol lasting 77 days.
  • This protocol was shortened to 42 days and evaluated in children with stage I to IV disease for EFS and toxicity.
  • The first dose of chemotherapy (COP1) consisted of 300 mg cyclophosphamide (CPM), 1 mg vincristine, and 60 mg prednisone given on day 1 and followed by COP2 on day 8 (only for patients with larger tumour volumes, stage III or IV disease).
  • RESULTS: Forty-two patients, 30 boys and 12 girls median ages 6 and 7.5 years, respectively, had Murphy stage I(n5), II(n8), III(n21), and IV(n8) disease.
  • Fourteen children died during or shortly after completion of chemotherapy.
  • The projected EFS at 12 months is 50% in stage I, 50% in stage II, 24% in stage III, 25% in stage IV, and 33% for all patients.
  • The morbidity and mortality of treatment was high.
  • [MeSH-major] Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Female. Humans. Malawi / epidemiology. Male. Methotrexate / administration & dosage. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / administration & dosage. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Malaria and HIV .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15547922.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


13. Hesseling PB, Broadhead R, Molyneux E, Borgstein E, Schneider JW, Louw M, Mansvelt EP, Wessels G: Malawi pilot study of Burkitt lymphoma treatment. Med Pediatr Oncol; 2003 Dec;41(6):532-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malawi pilot study of Burkitt lymphoma treatment.
  • BACKGROUND: Burkitt lymphoma (BL) accounts for 50% of childhood cancer in Malawi.
  • Lack of resources precludes the use of new successful treatment approaches such as the LMB 89 group B protocol, which cures >80% of children with stage III BL with high dose chemotherapy and matching supportive care.
  • Our objective was to achieve a good cure rate in Murphy stage I-III BL with manageable toxicity in Malawi at a drug cost of <1000 US dollars per patient.
  • PROCEDURE: The intensity and toxicity of the LMB 89 group B protocol was reduced and adapted to Malawi realities.
  • All stages received the same treatment.
  • Children with suspected BL in the period July 1997-November 1999 were subjected to abdominal ultrasound, a tumor biopsy and/or fine needle aspirate (FNA) and bone marrow (BM), cerebrospinal fluid (CSF), and peripheral blood examination.
  • RESULTS: Forty-four children were eligible for treatment and analysis.
  • Their median age was 7.2 years, M:F ratio 1.4:1 with 10 stage I, 5 stage II, and 29 stage III patients.
  • Projected Kaplan-Meier EFS for all was 57% (CI 41-73) at 1 year with 90% EFS in stage I and 52% EFS in stage III.
  • Toxicity and delays in appropriate supportive care contributed to ten deaths during treatment.
  • Local recurrent tumor caused five and CNS recurrence one death.
  • The incidence of severe (grade 3 and/or 4) hematologic toxicity varied from 13% to 36%, gastro-intestinal toxicity (GIT) from 2% to 17%, and infections from 7% to 41% per chemotherapy module.
  • CONCLUSIONS: It is possible to administer less intense and less costly multiagent chemotherapy to children with BL in a developing society with acceptable EFS rates.
  • Adequate supportive care of the at-times associated severe toxicity must be made available to better the results.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / economics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / economics. Developing Countries. Drug Costs

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 14595710.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Blayney DW, LeBlanc ML, Grogan T, Gaynor ER, Chapman RA, Spiridonidis CH, Taylor SA, Bearman SI, Miller TP, Fisher RI, Southwest Oncology Group: Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol; 2003 Jul 1;21(13):2466-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).
  • PURPOSE: To test the hypothesis that therapy of intermediate- and high-grade (excluding Burkitt lymphoblastic) lymphoma with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) could be safely dose-intensified with routine filgrastim support.
  • PATIENTS AND METHODS: Eligible patients were those who were previously untreated and who had either bulky stage II, or stage III or IV lymphoma with working formulation histology D, E, F, G, H, or J; performance status < or = 2; and acceptable end organ function.
  • Therapy was dose-intensified CHOP (CHOP-DI) with filgrastim support.
  • RESULTS: Eighty-eight eligible patients were treated with CHOP-DI and had a median follow-up of 5.1 years on this phase II study, designated Southwest Oncology Group (SWOG) 9349.
  • Three fatal treatment-related events occurred.
  • CONCLUSION: Treatment with CHOP-DI can be safely administered in the cooperative group setting and results in improved survival.
  • CHOP-DI, given every 2 weeks at escalated doses, is a strategy that should be tested in a future randomized clinical trial in lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Infusions, Intravenous. Injections, Subcutaneous. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2003 Jul 1;21(13):2457-9 [12829662.001]
  • (PMID = 12829664.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA04920; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA12213; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA35128; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35192; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA35262; United States / NCI NIH HHS / CA / CA35281; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA37981; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA45377; United States / NCI NIH HHS / CA / CA45450; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA46136; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA52386; United States / NCI NIH HHS / CA / CA52654; United States / NCI NIH HHS / CA / CA58416; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA63844; United States / NCI NIH HHS / CA / CA63845; United States / NCI NIH HHS / CA / CA63850; United States / NCI NIH HHS / CA / CA74647; United States / NCI NIH HHS / CA / CA76462; United States / NCI NIH HHS / CA / CA96429
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


15. Brichon P, Bertrand Y, Plantaz D: [Burkitt's lymphoma revealed by acute intussusception in children]. Ann Chir; 2001 Sep;126(7):649-53
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Burkitt's lymphoma revealed by acute intussusception in children].
  • [Transliterated title] Lymphome de Burkitt révélé par une invagination intestinale aiguë chez l'enfant.
  • STUDY AIM: Burkitt's lymphomas are rarely revealed by acute intestinal intussusception in children.
  • Abdominal ultrasonography showed intestinal intussusception (n = 8) primitive tumor (n = 2), mesentivic lymph nodes (n = 2) and liver nodes (n = 1).
  • A laparotomy was performed on emergency in seven patients and found the primitive tumor in 6.
  • The procedure consisted in disinvagination (n = 4) and intestinal resection for ischaemia (n = 2).
  • RESULTS: According to the Murphy classification, there were 2 stage II, 3 stage III and 3 stage IV patients.
  • With LMB protocol chemotherapy, a complete remission was observed following the first cure.
  • All the children were alive at the time of this study with a follow-up longer than one year after the complete remission.
  • In the absence of sonographic intestinal impair, thanks to ultrasonography guided tumoral puncture, diagnosis may be made and chemotherapy started.
  • If the lymphoma is not visualized with ultrasonography, an emergency laparotomy is necessary for the diagnosis of the lymphoma and the intestinal resection in case of necessity.
  • Burkitt's lymphoma is very sensible to chemotherapy.
  • [MeSH-major] Burkitt Lymphoma / complications. Intussusception / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11676236.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


16. Zhang YH, Duan YL, Yang J, Jin L, Zhou CJ, Gao ZF: [Clinical study of 40 children with Burkitt's and Burkitt-like lymphoma]. Zhonghua Er Ke Za Zhi; 2008 Mar;46(3):209-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of 40 children with Burkitt's and Burkitt-like lymphoma].
  • OBJECTIVE: To summarize the histological and clinical characteristics of 40 cases with Burkitt's and Burkitt-like lymphoma in children, to evaluate the effects of treatment with international regimen, and to explore the treatment-related complications and prognostic factors.
  • METHODS: Forty patients with Burkitt's and Burkitt-like lymphoma were registered in Beijing Children Hospital from Feb 2003 to Apr 2006.
  • The diagnosis was confirmed by histology and immunohistochemistry of biopsy, and clinical staging by the examination of imaging, cerebrospinal fluid and bone marrow based on St. Jude system.
  • Intensive, short-term chemotherapy witch was modified from LMB89 protocol was given to the patients.
  • RESULTS: Of the 40 patients, 30 were diagnosed as Burkitt's lymphoma (BL) and 10 as Burkitt-like lymphoma (BLL).
  • Nine cases were at stage I - II and 31 cases at stage III - IV at diagnosis; CNS was involved in 4 cases and bone marrow in 2 cases.
  • The courses of treatment were approximately 2 - 8 months.
  • After chemotherapy, 35 patients (88.7%) were still alive during the one-year follow-up.
  • Stage III to IV of myelosuppression occurred in the most patients with unresected tumor and CNS-involvement.
  • Of 5 patients who died, 2 died of infection, 2 died of lymphoma progression during chemotherapy, and 1 died of relapse.
  • CONCLUSION: Burkitt's and Burkitt-like lymphoma are the most common NHL in children with rapid clinical process.
  • Outcome was greatly improved by current intensive, short-term chemotherapy regimen, the 3-year EFS was 81.8% including the patients who were in advanced stage.
  • Childhood lymphoma with short clinical history, stage IV and residual disease after 3 months of therapy are associated with poor prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Male. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19099711.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


17. Eldar AH, Futerman B, Abrahami G, Attias D, Barak AB, Burstein Y, Dvir R, Gabriel H, Horovitz J, Kapelushnik J, Kaplinsky H, Miskin H, Sthoeger D, Toren A, Vilk-Revel S, Weintraub M, Yaniv I, Linn S, Arush MB: Burkitt lymphoma in children: the Israeli experience. J Pediatr Hematol Oncol; 2009 Jun;31(6):428-36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma in children: the Israeli experience.
  • BACKGROUND: We analyzed the results of the French-American-British-LMB 96 protocol performed in 9 centers in Israel on 88 patients with B-cell non-Hodgkin lymphoma treated from 2000 to 2005.
  • PROCEDURE: The majority of the patients was male (63/88, 72%), with a median age of 8.9 years (range, 2.5 to 20 y).
  • Fifty (57%) patients were classified as Burkitt lymphoma, 5 (5.7%) as Burkitt-like lymphoma, 22 (25%) as diffuse large B cell (DLBC), and 9 (10.2%) as Burkitt leukemia with over 25% of their bone marrow (BM) involved.
  • Stage I: 9.1%; stage II: 28.4%; stage III: 45.5%, stage IV: 17%.
  • RESULTS: With a median follow-up of 3 years (12 mo to 7.6 y), the Kaplan-Meier for event-free survival (EFS) and overall survival (OS) according to whole group treatment was 88.6% and 90.9%, group A was 100% and 100%; group B was 89.9% and 92.8%; and group C was 78.6% and 78.6%.
  • There were no untoward events or deaths in group A, whereas 6 patients relapsed in group B, 4 of whom died (all relapsed during the first year), with tumor lysis syndrome in 3 patients and death of toxicity in 1 patient who had multiorgan failure 2 days after initiation of COP.
  • Three patients in group C relapsed and died (all patients relapsed during the first 6 months), with tumor lysis syndrome in 4 patients but no deaths from toxicity.
  • CONCLUSIONS: In nonresected mature B-cell lymphoma of childhood and adolescence with no BM or CNS involvement, a 93% cure rate can be achieved, similar to the French-American-British/LMB 96 trial.
  • Patients with primary DLBC mediastinal mass had a significantly reduced OS, indicating the need for a different therapeutic approach.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / mortality
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Israel. Kaplan-Meier Estimate. Male. Neoplasm Recurrence, Local / pathology. Randomized Controlled Trials as Topic. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648792.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


18. Hesseling P, Molyneux E, Kamiza S, Israels T, Broadhead R: Endemic Burkitt lymphoma: a 28-day treatment schedule with cyclophosphamide and intrathecal methotrexate. Ann Trop Paediatr; 2009 Mar;29(1):29-34
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endemic Burkitt lymphoma: a 28-day treatment schedule with cyclophosphamide and intrathecal methotrexate.
  • BACKGROUND: Endemic Burkitt lymphoma (eBL) is the most common childhood cancer in equatorial Africa and there is a need for affordable, effective treatment.
  • AIM: To record the morbidity of treatment and event-free survival after 1 year using relatively high doses of cyclophosphamide at short intervals combined with intrathecal methotrexate.
  • Chemotherapy consisted of cyclophosphamide, 40 mg/kg on day 1 and 60 mg/kg on days 8, 18 and 28.
  • Allopurinol was commenced before chemotherapy, and a high urinary output was maintained to prevent tumour lysis.
  • RESULTS: St Jude stage distribution was stage I, 1; II, 9; III, 24; and IV, 6.
  • Two patients died during treatment, three had chemotherapy-resistant disease and 35 (88%) achieved complete clinical remission by day 28.
  • Sixteen required antibiotic treatment for presumed infection and nine received a blood transfusion.
  • CONCLUSION: This short, inexpensive treatment schedule (<50 US$) cured almost 50% of eBL patients in a setting of very limited resources.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Methotrexate / administration & dosage. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19222931.001).
  • [ISSN] 1465-3281
  • [Journal-full-title] Annals of tropical paediatrics
  • [ISO-abbreviation] Ann Trop Paediatr
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


19. Küpeli S, Varan A, Demir H, Aydin B, Yüce A, Büyükpamukçu M: Association of Helicobacter pylori and childhood lymphoma. J Pediatr Hematol Oncol; 2007 May;29(5):301-4
MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of Helicobacter pylori and childhood lymphoma.
  • We aimed to estimate the frequency of association between non-Hodgkin lymphoma (NHL) with abdominal, gastric, or intestinal involvement and Helicobacter pylori in childhood.
  • Patients who were given chemotherapy previously or who received H. pylori eradication therapy were excluded from the study.
  • Six had stage IV characteristics, whereas another 9 patients had stage III disease.
  • Ten had high-grade B-cell lymphoma.
  • First patient had T-cell lymphoma and stage IV disease with involvement in stomach, mediastinum, peripheral lymph nodes, and bone marrow.
  • The second one had anaplastic large cell lymphoma exclusively in abdominal lymph nodes.
  • Last patient had Burkitt lymphoma and stage IV disease, with primary tumor localization in abdominal lymph nodes, liver, and kidneys.
  • [MeSH-major] Gastrointestinal Neoplasms / epidemiology. Helicobacter Infections / epidemiology. Helicobacter pylori / isolation & purification. Lymphoma, B-Cell / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Anti-Bacterial Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Drug Therapy, Combination. Female. Humans. Male. Neoplasm Staging. Prospective Studies. Recurrence. Risk Assessment. Sampling Studies. Treatment Outcome. Turkey / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483706.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


20. Sun XF, Zhen ZJ, Liu DG, Xia Y, Xiang XJ, Chen XQ, Ling JY, Zheng L, Luo WB, Lin H, He YJ, Guan ZZ: [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents]. Ai Zheng; 2007 Dec;26(12):1339-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
  • BACKGROUND & OBJECTIVE: Burkitt's lymphoma is an aggressive non-Hodgkin's lymphoma (NHL) and often involves bone marrow and central nerve system.
  • The efficacy of CHOP regimen on Burkitt's lymphoma is poor.
  • The optimal chemotherapy regimen needs to be investigated.
  • This study was to evaluate the efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in children and adolescents, and observe the survival status.
  • 2006, 31 untreated Burkitt's lymphoma patients aged less than 20 were enrolled.
  • According to St Jude staging system, 1 (3.2%) was at stage I, 6 (19.4%) at stage II, 8 (25.8%) at stage III, 16 (51.6%) at stage IV; 24 (77.4%) were at stage III/IV.
  • According to clinical stage, lactate dehydrogenase (LDH) level and treatment response, these patients were divided into low, moderate and high risk groups.
  • They received modified B-NHL-BFM-90 protocol: cytotoxic drugs such as cyclophosphamide, vincristine, ifosfamide, etoposide, adriamycin, HD-methotrexate, vindesin, dexamethasone, cytarabinec/HD-cytarabine and intrathecal injection.
  • RESULTS: One patient died of tumor lysis syndrome during prophase.
  • Of the 30 patients, 25 (83.3%) achieved complete remission (CR), 3 (10.0%) achieved partial remission (PR), 2 (6.7%) had progressive disease (PD)û 1 had tumor relapse.
  • Grade 3-4 myelosuppression occurred in most patients and were recovered by active support care and did not affect next course of chemotherapy.
  • At a median follow-up of 33 months (range, 3-98 months), the 3-year event-free survival (EFS) rate was 86.0% for all patients, with 100% for stage I/II patients and 82.1% for stage III/IV patients, 100% for low risk group, 92.0% for moderate risk group, and 70.0% for high risk group.
  • CONCLUSIONS: Modified B-NHL-BFM-90 protocol can improve the responses and survival of Burkitt's lymphoma in Chinese children and adolescents, with tolerable toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076797.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


21. Sanpakit K, Veerakul G, Kriengsuntornkij W, Chokephaibulkit K, Tanphaichitr VS, Mahasandana C: Malignancies in HIV-infected children at Siriraj Hospital. J Med Assoc Thai; 2002 Aug;85 Suppl 2:S542-8
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Some malignancies such as Kaposi's sarcoma, non-Hodgkin's lymphoma (NHL) are one of the acquired immunodeficiency syndrome (AIDS)-defining illnesses.
  • With the improving survival of patients with AIDS due to better prevention and treatment of infectious complications, there may well be an increase in AIDS-related malignancies.
  • OBJECTIVE: To study malignancies in human immunodeficiency virus (HIV)-infected children in view of demographic data, HIV disease status, characters of malignancies, and treatment outcome.
  • All patients had NHL stage III or IV.
  • Burkitt's lymphoma was the predominant type.
  • Six patients were treated with appropriate chemotherapy and one patient also received antiretroviral therapy.
  • Only one patient with large cell lymphoma stage IV who received both antiretroviral and chemotherapy has survived to date.
  • Five patients died during chemotherapy treatment and one patient died before receiving chemotherapy.
  • One of them with Burkitt's lymphoma stage III also had central nervous system (CNS) relapse at the time of death.
  • Mean survival time after diagnosis with malignancies was 11 months (15 days-3 years 1 month).
  • Outcome of treatment is poor.
  • Adjustment protocol for treatment of malignancy in HIV-infected children combined with antiretroviral therapy for controlling HIV infection should be studied further.
  • [MeSH-major] Burkitt Lymphoma / epidemiology. HIV Infections / epidemiology. Lymphoma, AIDS-Related / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12403230.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


22. Otmani N, Khattab M: Oral Burkitt's lymphoma in children: the Moroccan experience. Int J Oral Maxillofac Surg; 2008 Jan;37(1):36-40
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral Burkitt's lymphoma in children: the Moroccan experience.
  • Thirty-seven children with Burkitt's lymphoma of the oral region diagnosed between 1998 and 2005 were reviewed.
  • According to the Murphy classification, there were 4 stage II, 11 stage III and 22 stage IV tumours; 43% and 41% had bone marrow and central nervous system involvement, respectively.
  • After chemotherapy, complete remission was seen in 59% of cases.
  • In conclusion, in this series, oral presentation of Burkitt's lymphoma was a component of more widely disseminated disease.
  • The pattern seemed to fall between that of the endemic and the sporadic types.
  • Even with intensive chemotherapy, patients with advanced disease maintained a poor prognosis.
  • [MeSH-major] Burkitt Lymphoma. Mouth Neoplasms

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17822883.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


23. Chen SW, Chang ST, Lu CL, Hwang WS, Tsao CJ, Huang WT, Chang KY, Chuang SS: Upper aerodigestive tract lymphoma in Taiwan. J Clin Pathol; 2010 Oct;63(10):888-93
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upper aerodigestive tract lymphoma in Taiwan.
  • AIM: To better understand the spectrum of primary lymphomas in the upper aerodigestive tract, a common site of extranodal lymphoma.
  • MATERIALS AND METHODS: Lymphoma cases diagnosed at an institution in southern Taiwan from 1992 to 2007 were retrospectively studied with pathology and history review, immunohistochemistry, in situ hybridisation for Epstein-Barr virus (EBER-ISH), and statistical analysis.
  • Phenotypically, there were 45 (64%) B cell and 25 (36%) T cell or extranodal natural killer (NK)/T cell lymphoma (ENKL) including 42 (60%) diffuse large B cell lymphomas (DLBCLs), 22 (31%) ENKLs, three unspecified peripheral T cell lymphomas, two follicular lymphomas and one Burkitt lymphoma.
  • Most patients received chemotherapy with or without radiotherapy.
  • The 5-year overall survival for all patients was 56.3% with B and T or NK/T cell lymphomas at 66.0% and 40.6%, respectively.
  • Univariate analysis revealed that sinonasal presentation, T or NK/T cell phenotype, raised lactate dehydrogenase (LDH) activity, and Ann Arbor stage III/IV diseases were associated with prognostically significant higher hazard ratio (HR) of lymphoma-related death.
  • CONCLUSIONS: Only a limited number of lymphoma entities occurred primarily in this anatomical region.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Child. Epidemiologic Methods. Epstein-Barr Virus Infections / complications. Female. Humans. L-Lactate Dehydrogenase / blood. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Lymphoma, B-Cell / virology. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / therapy. Lymphoma, T-Cell / virology. Male. Middle Aged. Mouth Neoplasms / pathology. Mouth Neoplasms / therapy. Mouth Neoplasms / virology. Neoplasm Staging. Prognosis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876320.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


24. Muwakkit SA, Razzouk BI, Shabb NS, Hancock ML, Dabbous I, Firzli S, Abboud MR: Clinical presentation and treatment outcome of children with Burkitt lymphoma in Lebanon: a single institution's experience. J Pediatr Hematol Oncol; 2004 Nov;26(11):749-53
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical presentation and treatment outcome of children with Burkitt lymphoma in Lebanon: a single institution's experience.
  • The authors reviewed the medical records of 42 children younger than 13 years of age diagnosed with Burkitt lymphoma at the American University of Beirut Medical Center between 1983 and 1993.
  • The total duration of treatment ranged from 6 to 18 months.
  • At a median follow-up of 5 years the event-free survival was 100% for children with stages I and II disease, 77.4% (+/- 2 SE) for stage III, and 0% for stage IV.
  • Failures in stage III patients were due to tumor lysis (3/24) and progressive disease (2/24).
  • Aggressive therapy with high doses of methotrexate and anthracyclines may not be necessary for the treatment of children with extensive abdominal disease (stage III) in Lebanon.
  • If confirmed in a larger series of patients, this study could have a major impact on the treatment of Burkitt lymphoma in Lebanon and other countries with limited resources.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Lebanon. Male. Methotrexate / administration & dosage. Neoplasm Staging. Prednisone / administration & dosage. Retrospective Studies. Treatment Failure. Treatment Outcome. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15543011.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; COMP protocol
  •  go-up   go-down


25. Lin H, Sun XF, Zhen ZJ, Xia Y, Xiang XJ, Ling JY, Liu DG, Xia ZJ, Huang HQ, Luo WB, Zheng L, Lin TY, Guan ZZ: [Clinical analysis of 69 cases of Burkitt's lymphoma]. Ai Zheng; 2008 Apr;27(4):425-8
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 69 cases of Burkitt's lymphoma].
  • BACKGROUND & OBJECTIVE: Burkitt's lymphoma is a kind of highly aggressive B-cell lymphoma.
  • There is no large-scale report concerning Burkitt's lymphoma in China yet.
  • This study was to summarize the characteristics of Burkitt's lymphoma in China.
  • METHODS: Clinical data of 69 Burkitt's lymphoma patients, treated from May 1985 to May 2007 in Cancer Center of Sun Yat-sen University, were analyzed.
  • RESULTS: Of the 69 patients, 44 were men and 25 were women, with a median age of 7 (range, 2-72); 5 were at stage I, 9 at stage II, 21 at stage III, and 34 at stage IV, advanced stage (stages III and IV) accounted for 55 (79.7%) patients.
  • Short-term and high intensive chemotherapy with central nervous system prophylaxis could improve the prognosis.
  • CONCLUSION: The clinical characteristics of these 69 Burkitt's lymphoma patients are much similar to those from sporadic areas, but the median age is lower, and the most common involved sites are cervical lymph nodes, abdomen and faciomaxillary-oropharynx.
  • [MeSH-major] Burkitt Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18423131.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


26. Bariakh EA, Zvonkov EE, Kremenetskaia AM, Kravchenko SK, Magomedova AU, Obukhova TN, Samoĭlova RS, Vorob'ev IA, Kaplanskaia IB, Moiseeva TN, Zybunova EE, Lorie IuIu, Chernova NG, Mar'in DS, Egorova EK, Krasil'nikova BB, Gabeeva NG, Vorob'ev AI: [Treatment of adult Berkitt-like lymphoma]. Ter Arkh; 2005;77(7):53-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of adult Berkitt-like lymphoma].
  • AIM: To compare programs of chemotherapy used in adult Berkitt-like lymphoma (ABLL); to assess efficacy and toxicity of the protocol AblL-M-04.
  • ABLL stage I, II, III and IV was diagnosed in 3, 5, 8 and 15 patients, respectively.
  • 10 patients had diffuse large B-cell lymphoma.
  • The modified protocol ABLL-M-04 of intensive short-term therapy included 10 patients, 2 of them pretreated.
  • RESULTS: Of 10 patients given CHOP or CHOP-like courses 9 were resistant to therapy, 2 died of rapid progression, 7 were converted to the program therapy.
  • Six patients died: 4 of progression, 2 of chemotherapy complications.
  • BLL-M-04 therapy was made in 9 patients: 7 patients persisted on the first remission, 2 patients died of chemotherapy complications.
  • Overall duration of the treatment was 3-3.5 months.
  • CHOP therapy cannot be recommended for patients with ABLL because of poor efficacy (all the CHOP patients died).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Adolescent. Adult. Asparaginase / therapeutic use. Cyclophosphamide / therapeutic use. Daunorubicin / therapeutic use. Disease Progression. Dose-Response Relationship, Drug. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Prednisolone / therapeutic use. Prednisone / therapeutic use. Retrospective Studies. Severity of Illness Index. Time Factors. Treatment Outcome. Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16116910.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; CHOP protocol; PVDA protocol; non-Hodgkin's lymphoma protocol 8503
  •  go-up   go-down


27. Wössmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A: Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol; 2003 Mar;82(3):160-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.
  • To evaluate the clinical benefit of the prophylactic use of urate oxidase in children with non-Hodgkin's lymphoma (NHL), we analyzed the incidence and complications of tumor lysis syndrome (TLS) in children with B-cell acute lymphoblastic leukemia (B-ALL) or stage III/IV Burkitt's lymphoma and a lactate dehydrogenase (LDH) level > or =500 U/l before and after the introduction of a protocol amendment to use urate oxidase for the prophylaxis of TLS.
  • From November 1997 all children with B-ALL or stage III and IV B-NHL and LDH > or =500 U/l should receive urate oxidase prophylactically (period 3).
  • Initial chemotherapy was identical.
  • Altogether, 78 children (4.4%) developed a TLS.
  • Patients with B-ALL had the highest risk to develop a TLS (26.4%) followed by B-ALL/Burkitt's lymphoma and a LDH > or =500 U/l (14.9%).
  • In period 1, 16.1% and 9.2% of the latter children developed a TLS or anuria, respectively, compared to 12.3% and 6.2% in period 3 ( p=NS).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Burkitt Lymphoma / drug therapy. Tumor Lysis Syndrome / prevention & control. Urate Oxidase / therapeutic use

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12634948.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 1.7.3.3 / Urate Oxidase
  •  go-up   go-down


28. Atra A, Gerrard M, Hobson R, Imeson JD, Hann IM, Pinkerton CR: Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols. Br J Haematol; 2001 Mar;112(4):965-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols.
  • Twenty-six children with B-cell acute lymphoblastic leukaemia (B-ALL) or Murphy Stage III or IV B-cell non-Hodgkin's lymphoma (B-NHL) progressed or relapsed after first-line therapy with a short, intensive multiagent chemotherapy regimen [United Kingdom Childhood Cancer Study Group (UKCCSG) 9003] (n = 62) or a slightly less intensive regimen (UKCCSG 9002) (n = 112).
  • Second-line therapy resulted in remission for eight patients (30%).
  • Three patients (11.5%) in the 9002 group, including one who never achieved CR in the primary site, are alive after second-line therapy.
  • High-dose therapy with stem cell rescue was used in only seven patients; its role needs to be studied further.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, B-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Bone Marrow Transplantation. Child. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / therapeutic use. Doxorubicin / administration & dosage. Etoposide / therapeutic use. Follow-Up Studies. Humans. Palliative Care. Prednisone / administration & dosage. Recurrence. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11298592.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


29. Yaniv I, Fischer S, Mor C, Stark B, Goshen Y, Stein J, Cohen IJ, Zaizov R: Improved outcome in childhood B-cell lymphoma with the intensified French LMB protocol. Med Pediatr Oncol; 2000 Jul;35(1):8-12
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved outcome in childhood B-cell lymphoma with the intensified French LMB protocol.
  • BACKGROUND: During the last 20 years, 120 children with B cell lymphoma were treated at the National Pediatric Hematology/Oncology Center of Israel.
  • PROCEDURE: Patient characteristics were similar in both groups except for stage of disease and lactate dehydrogenase (LDH) levels.
  • Significantly more patients in the LMB group had higher stage disease, and the LDH levels also were higher (<600 microg/ml).
  • Event-free survival for stages I, II, and III patients is 100%, and for stage IV 77%, whereas the overall event-free survival was 58% among 63 children treated previously, and for stage IV patients only 10%.
  • CONCLUSIONS: Intensive chemotherapy with a modified LMB protocol and modern supportive care result in a high cure rate of childhood B cell lymphoma even in patients with advanced disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / mortality
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Female. Humans. Israel / epidemiology. L-Lactate Dehydrogenase / blood. Male. Methotrexate / administration & dosage. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10881001.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; YL5FZ2Y5U1 / Methotrexate; MACHO protocol
  •  go-up   go-down


30. Straus DJ: Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma. Recent Results Cancer Res; 2002;159:143-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma.
  • Chemotherapy regimens similar to those used for non-Hodgkin's lymphoma (NHL) not associated with human immunodeficiency virus (HIV) infection have been used for patients with HIV-associated NHL with less success.
  • In a recent trial, patients with intermediate or high-grade NHL were randomized to either low-dose chemotherapy with methotrexate, bleomycin, doxorubicin, vincristine and dexamethasone (m-BACOD) or to standard-dose m-BACOD with sargramostim (granulocyte-macrophage colony-stimulating factor, GM-CSF).
  • Myelosuppression was greater with standard-dose chemotherapy.
  • In univariate and multivariate analyses of 21 pretreatment features of patients in this trial, four factors emerged as adversely prognostic with respect to survival: age >35 years, intravenous drug use, CD4 counts < 100/mm3 and stage III/IV disease.
  • In an analysis using the proportional hazards model, a "favorable" group was defined by patients with 0 or 1 adverse factor (median survival 46 weeks, survival at 144 weeks 29.5%) as compared with an unfavorable group with 3 or 4 adverse factors (median survival 18 weeks, survival at 144 weeks 0).
  • The outcome of these patients may be improving with the use of highly active antiretroviral therapy (HAART), which seems to improve immune function and tolerance of chemotherapy.
  • A recent trial of the AIDS Malignancy Consortium found that low-dose chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone: CHOP) and standard-dose chemotherapy had similar response rates, acceptable toxicity and minimal alterations in cyclophosphamide, doxorubicin and indinavir pharmacokinetics in HIV-associated lymphoma patients also on HAART (stavudine, lamivudine and indinavir).
  • There is a suggestion that Burkitt-type lymphomas may tend to occur in HIV-infected patients with relatively well preserved immune function and CD4 cell counts.
  • Recent results from our institution suggest that similar outcomes are achievable with intensive chemotherapy in patients with Burkitt's lymphomas with or without HIV infection.
  • With improved immune status and improved bone marrow function with the use of HAART, it will probably become more possible to treat many patients with aggressive HIV-associated NHL with more intensive treatment regimens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11785838.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Review
  • [Publication-country] Germany
  • [Number-of-references] 19
  •  go-up   go-down


31. Sun XF, Zhen ZJ, Lui DG, Xia Y, He YJ, Wang ZH, Lin JY, Guan ZZ: Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol. Eur J Haematol; 2006 Nov;77(5):365-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol.
  • OBJECTIVES: This study was designed to evaluate the efficacy and toxicity of the modified B-Non-Hodgkin's Lymphoma (NHL)-Berlin-Frankfurt-Münster (BFM)-90-based protocol in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma.
  • The patients were stratified by risk factors (stage, LDH level and chemotherapy response).
  • Of these patients, 22 (40%) had Burkitt's lymphoma (BKL), 22 (40%) had diffuse large B-cell lymphoma (DLBL) and 11 (20%) had anaplastic large T-cell lymphoma (ALCL).
  • At a median follow up of 24 months, the event free survival (EFS) for all patients was 85% +/- 5% with 100% for group R1, 84% +/- 7% for group R2 and 72% +/- 13% for group R3, and most notably, 80% +/- 6% for stage III/IV at diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Burkitt Lymphoma / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Asparaginase / administration & dosage. Asparaginase / adverse effects. Child. Child, Preschool. China. Daunorubicin / administration & dosage. Daunorubicin / adverse effects. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Male. Mucositis / chemically induced. Prednisone / administration & dosage. Prednisone / adverse effects. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879606.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


32. Hoffmeier A, Semik M, Schmid Ch, Mesters RM, Castrucci M, Baba HA, Fallenberg EM, Scheld HH: [Not Available]. Z Kardiol; 2002 Apr;91(4):347-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Primäres Burkitt-Lymphom des Herzens - Diagnose und Therapie.
  • An 85-year-old patient suffered from progressive deterioration (NYHA III) for several months.
  • Echocardiography as well as a CT scan of the heart revealed a heart tumor to be the cause.
  • Tumor staging was negative.
  • After transvenous biopsy, the diagnosis of a Burkitt lymphoma could be established.
  • Due to the advanced age of the patient, the intented surgical therapy was turned down and the patient was treated with 6 courses of a potentially therapeutic chemotherapy (CHOP scheme), which was well tolerated by the patient.
  • The following CT scan showed a complete remission of the tumor.
  • Six months after chemotherapy the patient is in NYHA stage I.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24756421.001).
  • [ISSN] 0300-5860
  • [Journal-full-title] Zeitschrift für Kardiologie
  • [ISO-abbreviation] Z Kardiol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


33. Boué F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, Billaud E, Raphael M, Lancar R, Costagliola D: Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol; 2006 Sep 1;24(25):4123-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
  • PURPOSE: To evaluate the safety and efficacy of rituximab adjunction to the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma.
  • PATIENTS AND METHODS: HIV-seropositive patients with high-grade lymphoma of B-cell origin were eligible if they had no more than one of the following characteristics: CD4 cell count less than 100/microL, prior AIDS, or performance status less than 2.
  • All the patients were assessable for safety and 52 were assessable for the tumor response after treatment completion.
  • Characteristics of patients were median age, 41 years; median CD4 cells, 172/microL; histology, diffuse large B-cell lymphoma (n = 42), immunoblastic (n = 2), Burkitt lymphoma (n = 16), and plasmablastic (n = 1); 42 patients with stage III to IV; International Prognostic Index 0 to 1 (n=31), and 2 to 3 (n = 27).
  • Grade 3 or 4 toxicity consisted of febrile neutropenia in nine patients, anemia in 16 patients, and thrombocytopenia in five patients.
  • Eighteen patients died: 16 as a result of lymphoma, one as a result of infection, and one as a result of encephalitis.
  • CONCLUSION: Rituximab adjunction to CHOP produced a CR rate of 77% and a 2-year survival rate of 75% in patients with AIDS-related non-Hodgkin's lymphoma, without increasing the risk of life-threatening infections.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Feasibility Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prognosis. Risk Factors. Rituximab. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Feb 20;25(6):e6 [17308260.001]
  • [CommentIn] J Clin Oncol. 2007 Feb 20;25(6):e7 [17308261.001]
  • (PMID = 16896005.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


34. Klumb CE, Schramm MT, De Resende LM, Carriço MK, Coelho AM, de Meis E, Ferreira RM, Maia RC, Dobbin Jde A: Treatment of children with B-cell non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil. J Pediatr Hematol Oncol; 2004 Jul;26(7):462-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of children with B-cell non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil.
  • PURPOSE: To treat non-Hodgkin's B-cell lymphoma (B-NHL) in children with manageable toxicity-related morbidity and without any decrease in survival.
  • The patients were stratified by risk factors (stage and LDH level) and treated with a BFM 86/90 (Berlin-Frankfurt-Münster)-based protocol with reduction of the methotrexate dose from 5 mg/m to 2 mg/m.
  • Seventy-two percent of the patients had lymphomas classified as Burkitt type, 11% as diffuse large cell lymphoma, and 6% as Burkitt-like lymphoma, and 11% were not classified.
  • The event-free survival rate for all patients was 78% (SE = 0.07): 100% (SE = 0.0) for stage I/II patients and 74% (SE = 0.08) for stage III/IV patients.
  • Six patients suffered initial treatment failure and one patient relapsed, all of whom died.
  • There was only one death from sepsis related to treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / therapeutic use. Daunorubicin / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Prednisone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Brazil. Child. Child, Preschool. Female. Humans. Infant. Male. Neoplasm Staging. Risk Factors. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15218425.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


35. Ahmad N, Zaidi A, Badar F, Maaz AU, Akram MS: Clinical characteristics and outcome analysis of pediatric B-cell non-Hodgkin's lymphoma. Experience with FAB-LMB 96 and UKCCSG B-cell NHL guidelines in a developing country. Asia Pac J Clin Oncol; 2010 Mar;6(1):49-56

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and outcome analysis of pediatric B-cell non-Hodgkin's lymphoma. Experience with FAB-LMB 96 and UKCCSG B-cell NHL guidelines in a developing country.
  • AIM: To analyze the clinical characteristics of B-cell non-Hodgkin's lymphoma (NHL) patients and the therapeutic efficacy of French-American-British Lymphoma Malins de Burkitt 96 and the recent United Kingdom Children's Cancer Study Group B-cell NHL guidelines in the tertiary care hospital of a developing country.
  • Of these 95 had Burkitt's lymphoma, 22 diffuse large B-cell lymphoma and five had B-cell NHL not otherwise specified.
  • A total of 37 had uric acid >10 mg/dl and 55 had a lactate dehydrogenase level >500; 73 had stage III and 31 had stage IV while only four presented at stage I and 14 at stage II.
  • A total of 45 patients died; 28 due to infection, nine due to tumor lysis syndrome and six of uncontrolled disease.
  • All deaths occurred within an average of 35 days from starting treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Practice Guidelines as Topic
  • [MeSH-minor] Child. Developing Countries. Female. Humans. Male. Neoplasm Staging. Pakistan. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20398038.001).
  • [ISSN] 1743-7563
  • [Journal-full-title] Asia-Pacific journal of clinical oncology
  • [ISO-abbreviation] Asia Pac J Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


36. Mottl H, Bajciova V, Nemec J, Al Shemmari S, Al Awadi S: High survival rate in childhood non-Hodgkin lymphoma without CNS involvement: results of BFM 95 study in Kuwait. Pediatr Hematol Oncol; 2003 Mar;20(2):103-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High survival rate in childhood non-Hodgkin lymphoma without CNS involvement: results of BFM 95 study in Kuwait.
  • Five children were treated by NHL BFM 90 protocol, 7 pts received NHL BFM 95 scheme, and 9 children underwent therapy abroad or according to different types of protocols.
  • Seven patients diagnosed with NHL--group B: 3 children with Burkitt lymphoma (B-cell NHL) and group A: 4 children with lymphoblastic lymphoma (T-cell NHL)--were treated from October 1995 to September 2000 in the Kuwait Cancer Control Centre according to NHL BFM 95 protocol.
  • Group B consisted of 2 girls and 1 boy; median age at diagnosis was 4 years 8 months, 2 pts classified as stage II and 1 pt as stage III.
  • Group A included 1 girl and 3 boys; median age at diagnosis was 5 years 8 months, 1 pt classified as stage III and 3 pts as stage IV.
  • In group B all 3 pts are in 1st CR; in group A 3 pts are in 1st CR and 1 pt having Li-Fraumani syndrome died after the 3rd relapse of disease during therapy.
  • In both groups there was no toxic death, myelotoxicity WHO grade III-IV, hepatotoxicity WHO grade II-III.
  • Treatment results of NHL BFM 95 study in our small group of patients are very optimistic.
  • [MeSH-major] Lymphoma, Non-Hodgkin / mortality
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / administration & dosage. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / mortality. Burkitt Lymphoma / surgery. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Infant. Kuwait / epidemiology. Leucovorin / administration & dosage. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / surgery. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / surgery. Male. Mesna / administration & dosage. Methotrexate / administration & dosage. Neoplasm Staging. Prednisolone / administration & dosage. Prednisone / administration & dosage. Survival Rate. Thioguanine / administration & dosage. Treatment Outcome. Vincristine / administration & dosage


37. Kersten MJ, Van Oers RH: Management of AIDS-related non-Hodgkin's lymphomas. Drugs; 2001;61(9):1301-15
Genetic Alliance. consumer health - AIDS-HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of non-Hodgkin's lymphoma in individuals infected with HIV is approximately 60- to 100-fold increased over the general population.
  • The majority of patients with AIDS-related lymphoma (ARL) present with stage III-IV disease and with B-symptoms.
  • Histologically, most tumours are either diffuse large cell lymphomas or Burkitt lymphomas.
  • Results of treatment with polychemotherapy compare unfavourably to results in patients without HIV infection.
  • Since the advent of highly active antiretroviral therapy (HAART), there appears to be a decrease in the incidence of ARL.
  • In addition, the use of HAART in combination with chemotherapy and the use of new treatment modalities may improve the outcome of this disease.
  • [MeSH-major] Lymphoma, AIDS-Related / etiology. Lymphoma, AIDS-Related / therapy. Lymphoma, Non-Hodgkin / etiology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Hematopoietic Cell Growth Factors / therapeutic use. Humans. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1996 Aug 1;78(3):517-26 [8697399.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2466-72 [1933784.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1094-103 [9060550.001]
  • [Cites] Cancer. 1994 May 1;73(9):2400-7 [8168044.001]
  • [Cites] N Engl J Med. 1986 Apr 3;314(14):874-9 [3005862.001]
  • [Cites] Cancer. 1971 Jul;28(1):89-98 [4938894.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Blood. 1992 Jul 15;80(2):498-504 [1320956.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):269-76 [10563433.001]
  • [Cites] Cancer. 1991 Aug 15;68(4):842-52 [1855183.001]
  • [Cites] J Exp Med. 1992 Jul 1;176(1):169-76 [1377222.001]
  • [Cites] Nature. 1984 Nov 29-Dec 5;312(5993):449-50 [6095104.001]
  • [Cites] Int J Epidemiol. 1997 Apr;26(2):400-7 [9169177.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1099-107 [8099121.001]
  • [Cites] J Nucl Med. 1993 Apr;34(4):567-75 [8455072.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] J Acquir Immune Defic Syndr. 1993 Mar;6(3):265-71 [7680712.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1691-702 [8355036.001]
  • [Cites] Blood. 1991 Apr 1;77(7):1527-33 [1849034.001]
  • [Cites] Nat Med. 1997 Nov;3(11):1242-9 [9359699.001]
  • [Cites] Ann Hematol. 1994 Dec;69(6):281-90 [7993935.001]
  • [Cites] Eur J Cancer. 2000 Feb;36(3):363-7 [10708938.001]
  • [Cites] Ann Intern Med. 1990 Aug 15;113(4):276-82 [1973886.001]
  • [Cites] Science. 1988 Sep 23;241(4873):1673-5 [3047875.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1758-67 [7541452.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 16;86(22):1711-6 [7966400.001]
  • [Cites] Blood. 1991 Mar 1;77(5):1092-5 [1847310.001]
  • [Cites] Leuk Lymphoma. 1992 Oct;8(3):213-20 [1283356.001]
  • [Cites] J Clin Oncol. 1999 Feb;17 (2):554-60 [10080599.001]
  • [Cites] Leuk Lymphoma. 1994 Jul;14(3-4):263-71 [7950915.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):3026-35 [8918501.001]
  • [Cites] AIDS. 1996 Jan;10(1):61-7 [8924253.001]
  • [Cites] Eur J Cancer. 1991;27(11):1416-23 [1660293.001]
  • [Cites] Cancer. 1999 Nov 1;86(9):1840-7 [10547559.001]
  • [Cites] Lancet. 1991 Oct 19;338(8773):969-73 [1681341.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Blood. 1993 Jul 15;82(2):619-24 [8392401.001]
  • [Cites] Blood. 1999 Mar 15;93(6):1838-42 [10068655.001]
  • [Cites] Ann Oncol. 1999 Feb;10(2):189-95 [10093688.001]
  • [Cites] Science. 1986 Sep 5;233(4768):1084-6 [3016902.001]
  • [Cites] Blood. 1994 May 15;83(10):2952-61 [8180391.001]
  • [Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]
  • [Cites] J Infect Dis. 1994 Jul;170(1):198-202 [8014498.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1289-98 [1325212.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3601-6 [9817281.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2391-7 [10590382.001]
  • [Cites] J Clin Oncol. 1987 Sep;5(9):1322-8 [2442321.001]
  • [Cites] J Natl Cancer Inst. 1997 Feb 19;89(4):301-7 [9048834.001]
  • [Cites] Am J Epidemiol. 1993 Jan 1;137(1):19-30 [8434570.001]
  • [Cites] Mol Cell Biol. 1986 Nov;6(11):3838-46 [3025615.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1982 Jun 4;31(21):277-9 [6808345.001]
  • [Cites] Med Oncol. 1998 Apr;15(1):50-7 [9643531.001]
  • [Cites] Blood. 1998 Feb 1;91(3):747-55 [9446632.001]
  • [Cites] Blood. 1990 Dec 1;76(11):2303-10 [2257304.001]
  • [Cites] Ann Oncol. 1998 Oct;9(10):1135-8 [9834829.001]
  • [Cites] Ann Oncol. 1992 Dec;3(10):843-7 [1286047.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3423-30 [7780129.001]
  • [Cites] Br J Haematol. 1995 Aug;90(4):844-9 [7669663.001]
  • [Cites] JAMA. 1989 Feb 3;261(5):719-24 [2536124.001]
  • [Cites] J Clin Invest. 1997 Apr 1;99(7):1525-33 [9119996.001]
  • [Cites] Am J Med. 1993 Aug;95(2):188-96 [7689296.001]
  • [Cites] Ann Hematol. 1999 Jan;78(1):9-12 [10037262.001]
  • [Cites] Blood. 1995 Dec 15;86(12):4612-6 [8541552.001]
  • [Cites] Ann Intern Med. 1996 Apr 1;124(7):654-63 [8607594.001]
  • [Cites] Ann Intern Med. 1988 May;108(5):744-53 [3358573.001]
  • [Cites] JAMA. 1991 Jul 3;266(1):84-8 [1710673.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9809-14 [10449776.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]
  • [Cites] J Exp Med. 1986 Dec 1;164(6):2049-60 [3491176.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1071-2 [10744095.001]
  • [Cites] Haematologica. 1998 Jun;83(6):508-13 [9676023.001]
  • [Cites] Ann Neurol. 1988;23 Suppl:S13-6 [2894803.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1978-84 [7692000.001]
  • [Cites] Leukemia. 1993 Oct;7(10):1621-9 [8412324.001]
  • [Cites] J Clin Oncol. 1991 Jun;9(6):929-40 [2033429.001]
  • [Cites] Blood. 1993 Apr 1;81(7):1889-97 [8461474.001]
  • [Cites] J Exp Med. 1994 Dec 1;180(6):2371-6 [7964510.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):328-32 [8625110.001]
  • [Cites] Ann Oncol. 1990;1(3):203-11 [2261366.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S31-3 [10430216.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1781-7 [1356511.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S11-7 [10430212.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Br J Haematol. 1999 Jun;105(3):795-8 [10354149.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1674-81 [8394878.001]
  • [Cites] Blood. 1997 May 15;89(10):3755-62 [9160681.001]
  • (PMID = 11511024.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Hematopoietic Cell Growth Factors
  • [Number-of-references] 96
  •  go-up   go-down


38. Temmim L, Baker H, Amanguno H, Madda JP, Sinowatz F: Clinicopathological features of extranodal lymphomas: Kuwait experience. Oncology; 2004;67(5-6):382-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 935 patients with extranodal non-Hodgkin lymphoma (NHL) diagnosed in the period between January 1985 and December 2000 in Kuwait Cancer Center, serving the whole population of Kuwait, were used to describe the clinicopathological and epidemiological features of extranodal lymphomas in Kuwait.
  • Extranodal lymphomas accounted for 45% of all NHL observed during this time.
  • The most common lymphoma observed was diffuse large B-cell lymphoma (58.60%) followed by Burkitt s lymphoma (BL) (3.80%).
  • The majority (73.40%) of adult extranodal lymphomas was in stage IE-IIE and had a very good prognosis.
  • On the contrary, the majority of pediatric extranodal lymphomas were found to be in stage III and IV.
  • Variations in treatment policies (single agent or combined chemotherapy, radiotherapy, combined modality treatment) adopted and changed during the time period of 16 years of this retrospective study were documented.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / pathology. Child. Child, Preschool. Female. Humans. Infant. Intestinal Neoplasms / epidemiology. Intestinal Neoplasms / pathology. Kuwait / epidemiology. Lymphoma, B-Cell / epidemiology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Registries. Retrospective Studies. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology. Stomach Neoplasms / epidemiology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 S. Karger AG, Basel
  • (PMID = 15713994.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


39. Tirelli U, Spina M, Jaeger U, Nigra E, Blanc PL, Liberati AM, Benci A, Sparano JA: Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study. Recent Results Cancer Res; 2002;159:149-53
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study.
  • iCDE) is one of the most effective chemotherapeutic regimen for human immunodeficiency virus (HIV)-associated non-Hodgkin's lymphoma (NHL), with a complete remission rate of 46% and a median overall survival of 8.2 months (Sparano JA, Blood 1993; 81:2810).
  • Characteristics of 29 evaluable patients were: median age: 38 years (range 29-65 years); male sex 24/29; histology: DLCL 16 (55%), Burkitt 10 (35%), ALCL 2 (7%), unclassified 1 (3%); stage: I (35%), II (10%), III (10%), IV (45%); International Prognostic Index: 0, 1 (59%), 2 (24%), 3 (17%), 4, 5 (0); CD4 count: median 132/ mm3 (range 3-470/mm3).
  • All patients were treated with G-CSF and highly active antiretroviral therapy (HAART).
  • Twenty-six of 29 patients received treatment as planned, while chemotherapy had to be discontinued in three patients (2 persistent thrombocytopenias, 1 cerebral hemorrhage).
  • Grade 3 or 4 toxicity was observed as follows: neutropenia 79%, anemia 45%, thrombocytopenia 34%, bacterial infection 34%, opportunistic infection 7%, mucositis 17%.
  • The high complete remission rate also indicates a potential therapeutic benefit and warrants further randomized trials.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Disease-Free Survival. Drug Therapy, Combination. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Rituximab. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11785839.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; ACE protocol 1
  •  go-up   go-down






Advertisement